Litcius/Paper detail

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer, Amylou C. Dueck, Miguel Martín, Gábor Rubovszky, Harold J. Burstein, M. Bellet-Ezquerra, Kathy D. Miller, Nicholas Zdenkowski, Eric P. Winer, Georg Pfeiler, Matthew P. Goetz, Manuel Ruíz‐Borrego, D. Mark Anderson, Zbigniew Nowecki, Sibylle Loibl, Stacy Moulder, Alistair Ring, Florian Fitzal, Tiffany A. Traina, Arlene Chan, Hope S. Rugo, Julie Lemieux, Fernando Henao, Alan P. Lyss, Silvia Antolín, Antonio C. Wolff, Marcus Vetter, Daniel Egle, Patrick G. Morris, Eleftherios P. Mamounas, Miguel Gil‐Gil, Aleix Prat, Hannes Fohler, Otto Metzger, Magdalena Schwarz, Carter DuFrane, Debora Fumagalli, Kathy Puyana Theall, Dongrui R. Lu, Cynthia Huang Bartlett, María Koehler, Christian Fesl, Angela DeMichele, Michael Gnant

2021The Lancet Oncology255 citationsDOI

Topics & Concepts

PalbociclibInterim analysisMedicineInterimAdjuvantOncologyBreast cancerInternal medicineCancerEndocrine systemAdjuvant therapyGynecologyClinical trialMetastatic breast cancerHistoryHormoneArchaeologyAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study | Litcius